These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 19739006

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Resistance of Leishmania infantum to Glucantime: risk factors and therapeutic management].
    Piarroux R, Garnier JM, Gambarelli F, Dumon H, Kaplanski S, Unal D.
    Arch Pediatr; 1996 Apr; 3(4):352-6. PubMed ID: 8762958
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of infantile visceral leishmaniasis].
    Minodier P, Faraut-Gambarelli F, Piarroux R, Gire C, Garnier JM, Dumon H.
    Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
    [Abstract] [Full Text] [Related]

  • 6. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, Pasquau J, Alvar J.
    AIDS; 1999 Jun 18; 13(9):1063-9. PubMed ID: 10397536
    [Abstract] [Full Text] [Related]

  • 7. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
    Gramiccia M, Gradoni L, Orsini S.
    Ann Trop Med Parasitol; 1992 Dec 18; 86(6):613-20. PubMed ID: 1304703
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F.
    Antimicrob Agents Chemother; 1996 May 18; 40(5):1214-8. PubMed ID: 8723469
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP, Sulahian A, Garin YJ, Derouin F.
    J Antimicrob Chemother; 1997 Aug 18; 40(2):287-9. PubMed ID: 9301998
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J, Portús M.
    BMC Pharmacol; 2002 May 02; 2():11. PubMed ID: 12019027
    [Abstract] [Full Text] [Related]

  • 12. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
    Pourabbas B, Ghadimi Moghadam A, Pouladfar G, Rezaee Z, Alborzi A.
    Am J Trop Med Hyg; 2013 May 02; 88(5):868-71. PubMed ID: 23400573
    [Abstract] [Full Text] [Related]

  • 13. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G.
    Int J Antimicrob Agents; 2005 Jan 02; 25(1):26-30. PubMed ID: 15620822
    [Abstract] [Full Text] [Related]

  • 14. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G, Mandal S, Sharma M, Charret KS, Papadopoulou B, Bhattacharjee H, Mukhopadhyay R.
    PLoS Negl Trop Dis; 2015 Feb 02; 9(2):e0003500. PubMed ID: 25714343
    [Abstract] [Full Text] [Related]

  • 15. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.
    Cascio A, Gradoni L, Scarlata F, Gramiccia M, Giordano S, Russo R, Scalone A, Camma C, Titone L.
    Am J Trop Med Hyg; 1997 Jul 02; 57(1):75-8. PubMed ID: 9242323
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J, Macías J, Pineda JA, Corzo JE, González-Moreno MP, de la Rosa R, Sánchez-Quijano A, Leal M, Lissen E.
    Am J Trop Med Hyg; 1999 Nov 02; 61(5):766-9. PubMed ID: 10586909
    [Abstract] [Full Text] [Related]

  • 19. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P, Retornaz K, Horelt A, Garnier JM.
    Fundam Clin Pharmacol; 2003 Apr 02; 17(2):183-8. PubMed ID: 12667228
    [Abstract] [Full Text] [Related]

  • 20. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR, de Jesus LCL, Soares RP, Silva LDM, Pinto BAS, Melo MN, Paes AMA, Pereira SRF.
    Antimicrob Agents Chemother; 2017 Jun 02; 61(6):. PubMed ID: 28320726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.